Propionic Acid

Propionic Acid

SCHEMBL4164331

CCC(=O)O.COc1cccc(NS(=O)(=O)c2ccc3[nH]c(=O)c4[nH]ccc4c3c2)c1

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.54
TP53 P04637 4/20 0.54
LMNA P02545 3/20 0.54
POLB P06746 11/20 0.51
TDP1 Q9NUW8 7/20 0.51
SMN1; SMN2 Q16637 6/20 0.51
ALDH1A1 P00352 4/20 0.50
HSD17B10 Q99714 3/20 0.50
L3MBTL1 Q9Y468 3/20 0.50
HPGD P15428 3/20 0.50
MAPK1 P28482 2/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
GAA P10253 2/20 0.50
ESR1 P03372 1/20 0.50
BRD4 O60885 1/20 0.49
PKM P14618 2/20 0.48
TSHR P16473 1/20 0.48
THRB P10828 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Propionic Acid SCHEMBL4157596 0.93 BRD4 (0.52) MAPTTP53LMNAPOLBTDP1
Propionic Acid SCHEMBL4163726 0.90 BRD4 (0.54) MAPTTP53LMNAPOLBSMN1; SMN2
Propionic Acid SCHEMBL4163285 0.89 PKM (0.54) MAPTTP53LMNAPOLBTDP1
Propionic Acid SCHEMBL4164250 0.88 BRD4 (0.62) MAPTTP53LMNAPOLBSMN1; SMN2
Propionic Acid SCHEMBL4155348 0.88 PKM (0.44) MAPTTP53LMNAPOLBKMT2A
Propionic Acid SCHEMBL4162436 0.88 MAPT (0.52) MAPTTP53LMNAPOLBSMN1; SMN2
Propionic Acid SCHEMBL4162704 0.88 BRD4 (0.52) MAPTTP53LMNAALDH1A1MEN1
Propionic Acid SCHEMBL4162624 0.85 MAPT (0.47) MAPTTP53LMNAPOLBTDP1
Propionic Acid SCHEMBL4161141 0.84 BRAF (0.53) MAPTTP53LMNAPOLBMEN1
Propionic Acid SCHEMBL4157756 0.84 BRD4 (0.63) LMNASMN1; SMN2ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US claimed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 MAPT 734/4885TP53 637/4885LMNA 3096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.